Top Tech Companies (36)
Biossil is an applied AI drug discovery platform founded to develop targeted therapies for biologically defined patient sub-populations. Our focus is on diseases for which traditional drug discovery has been challenged by population variability.
One trocar, three sizes, countless advantages
We are scientists, environmentalists and engineers with a belief in better materials. We believe in the power of plants to transform the zero-waste landscape. Single use plastics made with our solutions are compostable, and compatible with existing plastic technology, making plant powered plastics the natural choice. Established as a Canadian green technology company in 2018, we build solutions on a global scale. We're not reinventing the wheel - we're just making it more sustainable.
Evoco is a material innovation company harnessing the power of nature through plant-based chemistry to develop the next generation of high-performing, sustainable products.
Insight Medbotics is developing MRI-guided robotics to bring together the insights only MRI can provide with the minimally invasive access and precision of robotics. Our MRI-compatible robot, IGAR, has been clinically demonstrated in breast cancer patients. IGAR can be used for biopsy, targeted therapy delivery, and device placement. Our vision is to bring our advanced MRI-guided robotic technology to procedures where accuracy and precision matter most to patients, physicians and hospitals.
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications. Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals. We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. Currently, we have developed a combination product for post-operative pain, which is our company's lead project.
Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and subsidiaries located in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore, South Korea and the UK. For more information about New England Biolabs visit www.neb.com. We welcome you to our Linkedin community and we ask that you please follow our community guidelines, you can find them here: http://nebiolabs.com/community Visit us on Youtube for protocol and product videos: youtube.com/nebiolabs Follow us on Twitter: twitter.com/#!/nebiolabs
MedAvail Inc. is the developer of the MedCenter automated dispensing and medication management technologies. The company designs and manufactures pharmacist-controlled automated prescription medicine dispensing vaults, similar in appearance to ATMs. Intended for deployment in hospitals, pharmacies, medical clinics, and other locations. The company integrates advanced robotics, two-way video teleconferencing, and a secure network for patients medical information to create a prescription medication dispensing system.
Founded in 2012, GeneYouIn, the provider of Pillcheck, helps individuals and their healthcare providers choose the right medications to feel better sooner. Many health plans partner with Pillcheck to bring the positive health impacts of precision medicine to their members. Pillcheck was the first platform combining DNA analysis with clinical pharmacy services, and we remain leaders in the field. We operate in North America and Europe, complying with healthcare and data privacy regulations globally. Our multi-lingual software-enabled service integrates expert pharmacist reviews and delivers the consistent application of precision medicine insights for individuals, businesses, and healthcare providers. Pillcheck’s technology architecture addresses the demand for rapid deployment, flexible configuration, and evolving precision medicine programs over time based on data analysis. The Pillcheck platform automates the analysis of genetic data. It includes an auditable gateway for managing genetic and drug-reference information. In addition, the secure front-end web application facilitates role-based access for the provision of reliable DNA-guided prescribing. Clinical diagnostic laboratories in the US, Canada and Europe have independently validated our bioinformatics system. We partner only with certified clinical genetic laboratories
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.
Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies.
Pioneering next-gen precision therapeutics for diseases stemming from microtubule dysfunction, such as neuropathies and cardiovascular diseases.
Pillcheck is a genomics-guided personalized medication management service that predicts how medications work, limiting potential side effects and helping individuals feel better sooner. Pillcheck’s proprietary Enterprise Platform connects healthcare providers and consumers while reducing exposure to unnecessary costs for payers. Pillcheck works with insurers, corporate benefit plans, and benefits advisors to bring precision medicine to the workplace, following best practices around genetic non-discrimination legislation and health data privacy laws. Our Technology: The Pillcheck platform automates the analysis of genetic data. It includes an auditable gateway for managing genetic and drug-reference information. In addition, the secure front-end web application facilitates role-based access for the provision of reliable DNA-guided prescribing. Clinical diagnostic laboratories in the US, Canada and Europe have independently validated our bioinformatics system. We partner only with certified clinical genetic laboratories.
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.
Centricity Research is an integrated research organization (IRO) with more than 40 wholly owned and integrated clinical research offices across North America. The company conducts Phase I-IV clinical research in over 35 therapeutic areas: inpatient and outpatient; pharmaceutical, biotechnology, and medical device trials. For more than 25 years, the organization’s founders have worked to revolutionize research by investing in the people and technology needed to deliver outstanding clinical trial experiences, earning numerous awards including “Best Places to Work” and recognition for “Outstanding Diversity in Clinical Research.” Jobseekers: Apply here >> https://centricityresearch.applytojob.com/apply
Toronto-based infectious disease intelligence company, BlueDot, has developed a first-of-its-kind, global early warning technology for infectious diseases. Using artificial and human intelligence, BlueDot’s outbreak risk platform tracks over 120 infectious diseases globally in 65 languages, around the clock and anticipates their spread and impact. They empower national and international health agencies, pharma and life sciences companies, and businesses to better anticipate, and respond to, emerging threats. BlueDot was among the first in the world to identify the emerging risk from, and publish a scientific paper on, COVID-19, and delivers regular critical Insights to its partners and customers worldwide to mobilize timely, effective, efficient, coordinated, and measured responses. BlueDot was founded in 2013 by Dr. Kamran Khan, a practicing infectious disease physician, and Professor of Medicine with the Division of Infectious Diseases at the University of Toronto. Motivated by his experiences as a frontline healthcare worker during the 2003 Toronto SARS outbreak, Dr. Khan has been studying the outbreak of infectious diseases over the past 15 years to lay the scientific foundation for BlueDot’s early warning system.
